Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
28.83M | 38.02M | 485.42M | 375.20M | 233.16M | Gross Profit |
28.83M | 38.02M | 418.99M | 329.69M | 206.01M | EBIT |
-314.77M | -237.21M | 216.51M | 204.41M | 156.03M | EBITDA |
-204.15M | -192.16M | 272.20M | 241.62M | 169.62M | Net Income Common Stockholders |
-162.86M | -146.40M | 158.52M | 153.46M | 118.92M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
625.61M | 760.59M | 886.49M | 722.98M | 594.12M | Total Assets |
1.36B | 1.49B | 1.54B | 1.32B | 1.01B | Total Debt |
60.74M | 77.38M | 82.26M | 36.41M | 6.10M | Net Debt |
-95.58M | -55.94M | -304.28M | -439.73M | -588.01M | Total Liabilities |
304.47M | 335.78M | 307.63M | 292.84M | 175.03M | Stockholders Equity |
1.06B | 1.15B | 1.23B | 1.03B | 830.51M |
Cash Flow | Free Cash Flow | |||
-186.95M | -121.38M | 204.70M | 186.13M | 8.02M | Operating Cash Flow |
-108.56M | -43.88M | 277.36M | 244.58M | 22.69M | Investing Cash Flow |
121.41M | -221.11M | -352.63M | -332.25M | -119.78M | Financing Cash Flow |
12.77M | 10.36M | -1.63M | -3.89M | 683.65M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $736.26M | 4.04 | 28.12% | ― | 910.33% | ― | |
52 Neutral | $703.51M | ― | 222.83% | ― | 23.89% | 16.86% | |
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
49 Neutral | $741.99M | ― | -14.75% | ― | -24.17% | -9.24% | |
47 Neutral | $914.93M | 83.42 | -57.18% | ― | ― | ― | |
42 Neutral | $758.94M | ― | -70.98% | ― | 249.53% | 56.59% | |
42 Neutral | $972.70M | ― | -41.43% | ― | ― | 0.71% |
AbCellera Biologics reported its financial results for the year 2024, highlighting significant progress in transitioning to a clinical-stage biotech company. The company maintained a strong cash position with over $800 million in liquidity and is set to initiate Phase 1 clinical trials for its first two programs in 2025. Despite a net loss of $162.9 million, AbCellera advanced three additional molecules into the clinic, bringing the total to 16, and started nine new partner-initiated programs, reflecting its continued growth and strategic investments.